P.W. Bodell, E. Kodesh, F. Haddad, F.P. Zaldivar, D. M. Cooper and G.R. Adams

Skeletal muscle growth in young rats is inhibited by chronic exposure to IL-6 but preserved by concurrent voluntary endurance exercise

Running Head: Effects of IL-6 and exercise on skeletal muscle growth

Address correspondence to:

Gregory R. Adams, Ph.D.
Associate Professor
Department of Physiology & Biophysics
University of California, Irvine
Medical Sciences 1
Room D335
Irvine, CA 92697-4560

Voice = 949-824-5518
FAX = 949-824-8540
Abstract: Childhood diseases are often accompanied by chronic inflammation which is thought to negatively impact growth. Interleukin-6 (IL-6) is typically cited as an indicator of inflammation and is linked to impaired growth. This study was designed to isolate and identify potential effects of chronic IL-6 exposure on skeletal muscle growth during development. A second aim was to determine if endurance exercise, thought to antagonize chronic inflammation, would interact with any effects of IL-6. The muscles of one leg of rapidly growing rats were exposed to IL-6 or vehicle for 14 days. Subgroups of IL-6 infused rats were provided access to running wheels. Local IL-6 infusion resulted in ~13% muscle growth deficit (myofibrillar protein levels). Exercise (>4000 m·day⁻¹) prevented this deficit. IL-6 infusion increased mRNA for suppressor of cytokine signaling-3 (SOCS3) and tumor necrosis factor-α (TNFα), and this was not prevented by exercise. IL-6 infusion increased the mRNAs for atrogin, insulin-like growth factor-I (IGF-I) and IGF binding protein-4 (IGFBP4), and these effects were mitigated by exercise. Exercise stimulated an increase in total RNA (~19%) only in the IL-6 infused muscle suggesting that a compensatory increase in translational capacity was required to maintain muscle growth. This study indicates that IL-6 exposure during periods of rapid growth in young animals can retard growth possibly via interactions with key growth factors. Relatively high volumes of endurance type exercise do not exacerbate the negative effects of IL-6 and in fact were found to be beneficial in protecting muscle growth.

Key Words: Cytokine, Inflammation, Running, Protection
Introduction.  

A number of childhood disease states are accompanied by chronic inflammation (23, 29, 41, 51, 61, 83). In addition to overt disease states, conditions such as childhood obesity and metabolic syndrome are also marked by abnormal inflammatory mediators (59, 77). Interleukin-6 (IL-6) is often reported to be elevated in these conditions and is an indicator of chronic inflammation (72). However, there is evidence that IL-6 can serve in either a pro- or anti-inflammatory role (e.g., 62, 72). An anti-inflammatory role for IL-6 in disease states would explain the frequent correlation between systemic IL-6 levels and severity of the disease. In contrast to a potentially palliative role for IL-6, there is evidence to suggest that the growth defect associated with some childhood diseases involving chronic inflammation may be mediated by increased circulating IL-6, most likely via the depression of plasma IGF-I levels (20, 52). This conclusion is supported by the known potential for interactions between proinflammatory cytokines and growth factors such as growth hormone (GH) and insulin like growth factor -I (IGF-I) (20, 52, 79, 80). In particular, recent findings that cytokine and growth factor signaling share common intracellular pathways and negative feedback mechanisms (e.g., suppressor of cytokine signaling (SOCS) family) suggests a mechanism for interaction and possibly interference (6, 33, 34, 53, 66, 67, 71, 78, 82). 

In addition to observational studies, several attempts at intervention indicate that elevated levels of IL-6 per se may negatively impact growth. For example, transgenic mice that over express IL-6 have decreased growth that can be mitigated by IL-6 neutralizing antibodies (20, 21). Similarly, in animal models of inflammatory bowel disease (IBD), treatment with IL-6 neutralizing antibodies restores growth (7, 69). Recently, the therapeutic use of an antibody that prevents formation of the IL-6 – IL-6 receptor (IL-6R) complex has also shown great promise for the treatment of systemic juvenile idiopathic arthritis (JIA) (84).

We previously reported that chronic local infusion of non-systemic doses of IL-6 into targeted skeletal muscles of adult rats led to significant muscle atrophy, as evidenced by decreased total and myofibrillar protein content (39). In the context of the broader literature, we interpret this finding as an indication that IL-6 per se has direct effects on skeletal muscle that result in catabolism. Recently, van Hall et al. reported
that acute systemic infusion of IL-6 into healthy human subjects, at levels that stimulate an intense exercise response, caused a decrease in muscle protein synthesis and therefore a small increase in net muscle protein break down (86). These authors speculated that this effect was due to an IL-6 induced decrease in circulating amino acid pools rather than a direct effect of IL-6 on muscle. Alternatively, there is substantial evidence that IL-6 can activate AMP-kinase (AMPK) in a number of tissues including skeletal muscle cells (5, 28, 68). In skeletal muscle, Bolster et al. reported that AMPK activity suppresses protein synthesis in the rat by down-regulating mammalian target of rapamycin (mTOR) signaling (12). A number of subsequent studies have verified that AMPK can down regulate protein synthesis via its effects on the mTOR pathway (24, 48). This mechanism can explain the observation that IL-6 decreases the activity of p70 S6 kinase (S6K) (28), a substrate of mTOR and a critical regulator of translation (42, 46).

The relationship between IL-6 and skeletal muscle in particular presents a paradox. Muscle cells are known to produce IL-6 in culture and in vivo (9, 35). In muscle, IL-6 has the potential to stimulate myoblast or satellite cell proliferation, (13, 64) and promote angiogenesis, all features indicative of anabolic processes (19). However, a number of studies have also established that chronic IL-6 exposure can have catabolic effects on skeletal muscle (31, 39, 65). It is most likely that some of the seemingly paradoxical effects of IL-6 exposure may be related to temporal factors. For example, chronic exposure, as seen during inflammation, may have very different effects from acute increases such as those seen with exercise. However, one concern would be the overlay of exercise induced IL-6 on a background of chronic inflammation.

Although increases in systemic levels of IL-6 often correlate with manifestations of a given disease state, there have been few in vivo studies that have assessed the direct impact of chronic elevations of IL-6 on specific tissues in the absence of substantial systemic effects. As noted above, evidence from studies which counter the effects of IL-6 also indicate that this cytokine can exert catabolic effects. However, these systemic studies cannot speak to the question of mechanisms by which IL-6 may effect specific tissues. The current work was designed to measure the effects of elevated IL-6 on skeletal muscle in the absence of a more generalized, systemic, elevation of this cytokine. Specifically, we focused on the imposition of a local elevation of IL-6 on
skeletal muscle during a period of rapid developmental growth—such as would occur in a growing child who suffers from an inflammatory disease. A second aim of this work was to measure the interactive effects of chronic IL-6 elevation and endurance mode exercise on muscle growth.

For this study, our working hypotheses were that chronic IL-6 exposure would negatively impact muscle growth and that exercise had the potential to exacerbate this effect. To test these hypotheses chronic IL-6 exposure, localized to one skeletal muscle was imposed in rapidly growing rats. Changes in muscle growth and molecular markers of muscle anabolic (e.g., IGF-I system, myostatin, etc.) and catabolic (e.g., atrogin) regulators were measured. In addition, molecular markers of potential cytokine-growth factor interactions (SOCS) were evaluated.
Methods

Animals The protocols use in this study were approved by the UCI institutional animal care and use committee.

Four-week old Female Sprague-Dawley rats were purchased from Taconic Farms. Rats were initially housed in groups of four with access to non-instrumented mouse running wheels to allow for familiarization with running. Approximately one week later, rats were single housed with access to a full sized rat running wheel and the running distance of each rat was determined for two days. Following this screening period, rats whose running distances deviated from the mean by one SD were removed from the potential study population to avoid introducing a bias by including animals with widely varying running behaviors.

The pump implantation surgery was considered to be the start of the study. At this time, the rats were ~5.5 weeks of age and body mass was $118 \pm 1$ g (n = 36). Rats were randomly assigned to one of three groups: Sham group rats received unilateral implantation of a mini-osmotic pump and catheter filled with vehicle. IL-6C group rats received unilateral implantation of pumps and catheters filled with IL-6 (recombinant Rat IL-6, Sigma # I0406). R-IL-6 group rats also received unilateral implantation of pumps and catheters filled with IL-6. For the duration of the study, Sham and IL-6C rats were single housed in standard vivarium cages with access to food and water ad libitum. R-IL-6 rats were housed in standard size vivarium cages fitted with Nalgene rat running wheels instrumented to record revolutions and were allowed access to food and water ad libitum.

Local Infusion The local infusion protocol used in this study has been described in previous publications (4, 36, 39). Infusion was accomplished via a catheter (0.006” I.D. Teflon, Cole-Parmer) attached to a mini-osmotic pump (Alzet model 2002, Alza Corp.). The mini-osmotic pumps were filled under aseptic conditions following the manufacturer’s instructions. For catheter implantation the rats were anesthetized with (ketamine/acepromazine, $80/2$ mg $\cdot$ kg$^{-1}$) and incisions were made in the skin overlying the gastrocnemius muscle (~1.5 cm incision) and on the back (~0.5 cm incision).
For these small animals, the catheter placement was modified relative to the previous studies (4, 36, 39). In this instance the fenestrated catheter tip was placed adjacent to the target muscle as opposed to being inserted under the muscle fascia. The catheter was passed through the biceps femoris muscle then placed between the lateral and medial heads of the gastrocnemius well distal to the location of nerves and blood vessels. The catheter fenestrations were oriented toward the medial head of the gastrocnemius (MG). The distal end of the catheter was closed off and secured to the plantaris tendon with sutures (4-0 Ethicon). The proximal end of the catheter was tunneled under the skin to the back incision. The proximal end of the catheter was then mated with the osmotic pump which had been primed by preincubation in sterile saline at 37°C. The pump was then placed under the skin via the back incision and both incisions were closed. At the termination of the infusion protocols the osmotic pumps were removed and any remaining infusate was aspirated via a syringe to verify pump function.

Previous work has demonstrated that the local infusion of vehicle \textit{per se} does not result in change in any measured variables (4, 17, & Adams unpublished). In the current study, the Sham infused rats experienced the same procedures as the IL-6 infused animals with exception that IL-6 was excluded from the muscle infusate to reconfirm that vehicle infusion had no effect on muscle mass.

\textbf{IL-6 Dose.} In children, conditions such as congenital heart disease, chronic renal failure, insulin dependent diabetes, sickle cell disease, Crohn's disease and juvenile idiopathic arthritis (JIA) are associated with circulating IL-6 levels reported to range from 10 to 71 ng /L (7, 23, 29, 41, 51, 55, 61, 83). In the current study, the dose of IL-6 delivered to the target muscle was designed to simulate a modest level of systemic IL-6 elevation (22 ng / L). This dose would be similar to that seen chronically in systemic JIA (51, 55, 61) but also similar to the plasma IL-6 levels transiently attained following strenuous exercise (58, 76).

The dose of IL-6 selected for this study the same as that used in a previous study in adult rats (39), e.g., 0.0014 pg / mg muscle /hour. Assuming a blood volume of \sim7 ml in \sim100 g rats (22), an equivalent systemic dose of IL-6 would be 0.154 ng. The objective of the current study was to deliver a dose reflecting a somatic dose of 0.154ng
to just the target muscle, hence 0.28 pg / muscle assuming a starting muscle mass of 200 mg for an ~100g female. In the current study, the dose of 0.28pg, if it were delivered to the systemic circulation, would equal 0.04pg/ ml or 40 pg/ l. It is important to note that, with regards to the whole body, the IL-6 dose used is vanishingly small ( compare 40 pg to 22 ng from 76) and many times lower than would be used for sepsis related studies (54, 87). Vehicle for this study consisted of 0.9 % saline.

Tissue Collection & Analysis. Fourteen days after the implantation surgeries, the rats were killed using Pentosol euthanasia solution. The rats were killed within two hours of the end of he dark cycle when most running activity occurs. After the induction of deep anesthesia, but prior to the cessation of breathing, blood was collected from the left ventricle via the diaphragm using a heparinized syringe. The ventricles were removed and weighed. The soleus, plantaris, MG, lateral gastrocnemius (LG) and tibalis anterior (TA) muscles of both the infused and contralateral leg were dissected free of connective tissue, weighed, snap frozen and stored at -80°C for later analysis.

Outcome Variables. The data reported in this study include measures of muscle growth and anabolic potential. Molecular indicators of the anabolic state of the muscle were selected based on an extensive history of work by our group and others that have established their relevance in the context of the regulation of muscle size in rodents and humans (e.g., 1, 10).

Muscle Protein Analysis. Muscle protein was determined from whole muscle homogenates using the Biuret method (32). Total muscle protein was calculated from the product of the concentration and the wet weight of the muscle sample recorded at sacrifice. Total myofibrillar protein was determined as previously described using a modification of the method of Solaro et al. (36, 73).

DNA Determination. DNA concentration was measured in whole muscle homogenates using a fluorometric assay for the DNA binding fluorochrome bisbenzimide H-33258 (Calbiochem, San Diego, CA). Calf thymus DNA was used as a standard (49).

Total RNA Isolation. Total RNA was extracted from pre-weighed frozen muscle samples using the TRI Reagent (Molecular Research Center, Cincinnati, OH) according to the company’s protocol, which is based on the method described by Chomczynski (18). Extracted RNA was precipitated from the aqueous phase with isopropanol, and
after washing with ethanol, dried and suspended in a known volume of nuclease free water. The RNA concentration was determined by optical density at 260 nm (using an OD260 unit equivalent to 40 μg/ml). The muscle total RNA concentration is calculated based on total RNA yield and the weight of the extracted muscle piece. The RNA samples were stored frozen at -80 °C to be used subsequently in determining the specific mRNA expression using relative RT-PCR procedures.

Reverse Transcription (RT). One μg of total RNA was reverse transcribed for each muscle sample using the SuperScript II RT from Gibco BRL and a mix of oligo dT (100 ng/reaction) and random primers (200 ng/reaction) in a 20μl total reaction volume at 45°C for 50 minutes, according to the provided protocol. At the end of the RT reaction, the tubes were heated at 90°C for 5 minutes to stop the reaction and then were stored at -80°C until used in the PCR reactions for specific mRNA analyses.

Polymerase Chain Reaction (PCR): As described previously (36, 81), relative RT-PCR method using 18S as internal standard (Ambion, Austin, TX) was applied to study the expression of specific mRNAs of interest including and IGF-I. We have previously published the sequence for the IGF-I primers (37). The primer sequences for SOCS-2, SOCS-3, Atrogin-1, MURF-1, and myostatin have also been published previously (27, 39). The primers used for IL-6 and its receptor and TNFα and its receptor are provided in Table 1. Primers were purchased from Life Technology, Gibco. All primers were tested for their compatibility with the alternate 18S primers. It was verified that 18s was not different between groups.

In each PCR reaction, 18S ribosomal RNA was co-amplified with the target cDNA (mRNA) to serve as an internal standard and to allow correction for differences in starting amounts of total RNA. The 18S primers were mixed with competimers at an optimized ratio that could range from 1:4 to 1:10 in order to bring down the 18S signal, which allows its linear amplification to the same range as the co-amplified target mRNA (10, Ambion, Relative RT-PCR kit protocol).

For each specific target mRNA, the reverse transcription and PCR reactions were carried under identical conditions using the same reagents premix for all the samples to
be compared in the study. To validate the consistency of the analysis procedures, at least one representative from each group was included in each RT-PCR run.

Amplifications were carried out in a Stratagene Robocycler with an initial denaturing step of 3 minutes at 96°C, followed by 25 cycles of 1 minute at 96°C, 1 minute at 55°C (55-60°C depending on primers), 1 minute at 72°C, and a final step of 3 minutes at 72°C. PCR products were separated on a 2-2.5 % agarose gel by electrophoresis and stained with ethidium bromide, and signal quantification was conducted by laser scanning densitometry, as reported previously (81). In this approach, each specific mRNA signal is normalized to its corresponding 18S. For each primer set, PCR conditions (cDNA dilutions, 18S competimer/primer mix, MgCl2 concentration, and annealing temperature) were set to optimal conditions, so that both the target mRNA and 18S product yields are in the linear range of the semilog plot when the yield is expressed as a function of the number of cycles (11). Selected PCR results (SOCS3, Atrogin and 18s) were confirmed using real-time PCR.

Immunoblot. As reported previously (38) the total amount insulin (Y1146)/IGF-I (Y1131) receptor and SOCS3 protein was examined by immunoblotting using antibodies from Cell Signaling Technology.

Plasma Cytokine Measurements Blood Sampling and Analysis. Aliquoted plasma was stored at -80°C until assayed. Secreted cytokine levels in rat plasma were measured using commercially available ELISA kits manufactured by R&D Systems (Minneapolis, MN). Cytokines measured were: Interleukin 1β; (IL-1β), with an intra-assay CV of 4.1 – 5.7%, inter-assay CV 3.9 – 8.8% and sensitivity ≤ 5.0 pg/ml; Tumor Necrosis Factor Alpha; (TNFα) with an intra-assay CV of 2.1–5.1%, inter-assay CV 8.8–9.7% and sensitivity ≤ 5.0 pg/ml; Interleukin-6 (IL-6), with an intra-assay CV 4.5-8.8%, inter-assay CV 7.0 – 10.0% and sensitivity of 22 pg/ml.

Muscle MHC Protein Determination Skeletal muscle MHC proteins were separated on acrylamide gels (10% T, 2.5% C) using a standard sodium dodecyl sulfate-polyacrylamide gel electrophoretic (SDS-PAGE) technique. Briefly, 2.5 µg of total denatured protein were loaded per lane. The gels were run at constant current (30 mA) for ~2.5 h at 22°C. At the completion of electrophoresis, the gels were stained with Brilliant Blue G 250 (Sigma Chemical), destained, and then scanned using a Molecular
Dynamics Laser Scanning Personal Densitometer (Sunnyvale CA). The MHC bands were identified based on their molecular weight and comparisons with purified protein. The intensity of the bands of interest was calculated via volume integration which is based on the sum of pixel density within a rectangle containing the entire band with local background correction (Image Quant Software, Molecular Dynamics).

Statistical analysis  All values are reported as mean and standard error of the mean (SEM). Between muscle and between group analysis was conducted using a One-Way ANOVA and SNK post test (PRISM- Graphpad). For statistical purposes, all comparisons included the contralateral and treatment muscles from each animal including SHAM. Pearson’s Correlation analysis was used to assess the relationship between IGF-I and Col-3 mRNA using the Prism software package. For all statistical tests the 0.05 level of confidence was accepted for statistical significance.
Results

**Muscle Effects - Sham** As previously reported by us and others, no differences detected in any of the measured variables between the vehicle infused and contralateral muscles of the Sham rats (4, 17, 36, 39). Data from the contralateral Sham muscles have been omitted from the graphical representations but were included in the statistical analyses.

**Somatic Effects of Local Muscle IL-6 Infusion and Exercise** The young female rats in this study increased in body mass by approximately 45% in the Sham and IL-6C groups (Fig. 1). The rats in the R-IL-6 group exhibited 39% body mass increase. Lesser body weight gains are commonly observed in female rats provided unlimited access to running wheels (e.g., 8, 57).

Relative to body mass, the mass of the left ventricle from the IL-6C rats was not different from that of the Sham group but was 6.8% lower (p<0.05) than that of the R-IL-6 rats (Sham: 2.56±0.03; IL-6C: 2.50±0.03; R-IL-6: 2.67±0.06 mg / g body)

Circulating (plasma) levels of proinflammatory cytokines associated with IL-6 were determined at sacrifice. Plasma IL-6 levels of the Sham rats were similar to those recently reported by others (e.g., 16, 47). The plasma IL-6 levels of the IL-6C rats were significantly depressed (-32%) relative to Sham (Fig. 2A). Exercise appeared to counter this decrease in circulating IL-6 such that the levels seen in the R-IL-6 group were not statistically different from those of the Sham rats (Fig. 2A). In pilot studies we found that 14 days of voluntary running had no effect on circulating IL-6 levels (data not shown).

Plasma IL-1β levels were also depressed in the IL-6C rats as well as the R-IL-6 animals (Fig. 2B). The plasma levels of TNF-α appeared to follow a similar pattern to those of IL-6 (Fig. 2C). However, no statistically significant changes were detected.

**Run Distances** The rats provided with running wheels (R-IL-6 group) averaged 4462±682 meters per day over the course of the study. The final six days of the study, this average was 5561±565 meters.
Muscle DNA No differences were detected in the concentration of DNA present in the MG muscles from any group (not shown).

Muscle - Exercise Effects Voluntary running resulted in a number of responses that were independent of the IL-6 treatment, i.e., they occurred in both the infused and contralateral muscles exclusively in the R-IL-6 group.

As might be expected, there was a reduction in the proportion of type IIb myosin heavy chain (MHC) protein and an increase in the proportion of type IIa in the MG muscle (Fig. 3). This is a classical phenotypic shift observed in many training studies (3). IL-6 infusion had no impact on this process.

The expression and/or accumulation of the mRNA for the IL-6 receptor subunit was significantly increased in both the IL-6 infused and contralateral muscles of the running group (Fig. 4) but not in the Sham or IL-6C groups.

The mRNA levels of two members of the suppressors of cytokine signaling (SOCS) family appeared to be depressed in the muscles of running rats, apparently independent of IL-6 infusion status. The mRNA for CIS was significantly decreased in the IL-6 infused muscles of runners while that of the contralateral muscle was not different from the infused but failed to achieve significance at the 0.05 level relative to other groups (Fig. 5A). The mRNA for SOCS2 also appeared to be decreased in response to exercise in the contralateral muscle (Fig. 5B).

Muscle - IL-6 Effects Sensitive to Exercise A number of IL-6 induced changes in skeletal muscle appeared to be, to some extent, countered by exercise. The IL-6 infused muscles of sedentary rats demonstrated a significant retardation in growth. This is evidenced in the 13% lower content of both total and myofibrillar protein relative to the contralateral muscles (Fig. 6). No deficit was seen in this parameter in muscles from either the Sham or R-IL-6 groups. Similarly, the MG muscle mass of the IL-6C infused muscles was significantly less than that of the contralateral muscle (2.0±0.04 vs. 2.2±0.04 mg / g body, P= 0.03). There were no significant differences in MG mass in the Sham or R-IL-6 groups. In addition, the mass of the Soleus, Plantaris and LG muscles of the IL-6C rats did not differ between legs (data not shown).
IL-6 infusion resulted in an increase in the levels of mRNA for IGF-I and IGFBP4 (Fig. 7A & B). This response was partially (IGFBP4) or completely (IGF-I) attenuated by the running exercise (Fig. 7A & B).

IL-6 infusion resulted in an increase in the protein levels of the IGF-I / Insulin Receptor (IGFR1) (Fig. 8). Running exercise also increased the levels of this protein. However, no additional increases in IGFR1 protein were observed in the IL-6 infused muscles of the running group (Fig. 8).

The abundance of the mRNA for Procollagen III (Col-3) was significantly increased in the IL-6C, infused muscles (Fig. 9). The increase in Col-3 mRNA was blunted by running exercise in the R-IL-6 rats.

The mRNA levels of both atrogin and cyclin dependent kinase inhibitor p21 (p21) were significantly increased by IL-6 infusion (Fig. 10 A & B). This response was partially blunted by running exercise such that any changes were no longer significant.

The total RNA content of the R-IL-6, infused (but not contralateral) muscles was significantly increased. This result suggests a positive interactive effect of these two treatments on the protein translational capacity of these muscles (Fig.11A).

**Muscle - IL-6 Effects Not Sensitive to Exercise** IL-6 infusion resulted in a similar decrease in the ratio of total protein (mg) to total RNA (μg) in the muscles of both the IL-6C and IL-6R rats (Fig. 11B).

IL-6 infusion resulted in an increase in the mRNA for TNF-α in the muscles of the IL-6C rats (Fig 12A). The TNF-α mRNA levels in the muscles of the R-IL-6 rats appeared to follow a similar pattern. However, the increase in TNF-α mRNA in the R-IL-6 infused muscles was not significant at the 0.05 level.

The mRNA for the TNF-α receptor was significantly increased in the IL-6 infused muscles of both the IL-6C and R-IL-6 groups (Fig. 12B).

The levels of mRNA for SOCS3 were also significantly increased in both groups of IL-6 infused muscles (Fig. 13). However, there were no significant differences detected in SOCS3 protein levels (Fig. 13).
**Muscle - No Effects** None of the treatment or control muscles demonstrated statistically significant differences in the mRNA levels for: IL-6, Myogenin, Cyclin D1, IGFBP5, or Myostatin (data not shown).
Discussion

A number of chronic diseases in children are associated with systemic inflammation as evidenced by increased levels of proinflammatory cytokines. The primary rationale for the current study was the need to distinguish the direct effects of IL-6, during developmental growth in skeletal muscle, from more complex, indirect and generalized effects that might result from delivery of the IL-6 to the whole body. The current study was designed to determine if chronic IL-6 exposure would interfere with the growth of a single targeted muscle in rapidly growing rats and whether endurance mode exercise would have an interactive effect on this process.

IL-6 INDUCED MUSCLE GROWTH RETARDATION In the current study we found that localized IL-6 infusion resulted in an apparent decrement in muscle growth. In particular, the IL-6 infused muscles of the sedentary IL-6 group (IL-6C) had 13% lower myofibrillar protein content than the contralateral muscles (Fig. 6B). This magnitude of myofibrillar protein deficit is similar to that seen when the effects of IGF-I were blocked by local infusion of an inhibitor of one component of IGF-I intracellular signaling in a previous study (36).

In contrast to our original hypothesis, voluntary running appeared to protect muscles exposed to chronic elevations in IL-6 from the growth inhibiting effect of IL-6 exposure but did not promote a hypertrophy response (e.g., R-IL-6 vs. Sham) (Fig. 6B). One possible explanation for this result might be that the increased contractile activity simply served to flush the infused IL-6 from the local muscle environment. However, it was observed that the mRNA for SOCS3 was elevated equally in both the IL-6C and R-IL-6 infused muscles (Fig. 12C). In the context of IL-6, SOCS3 is a known target of IL-6 signaling, serving as part of a negative feed back mechanism (6, 75). While increased SOCS3 expression is not exclusive to IL-6 signaling, in the current study it was found only in the IL-6 infused muscles. We therefore interpret this result as a validation of the efficacy of IL-6 delivery protocol used in this study.

Localized exposure to chronically elevated IL-6 did not appear to effect the developmental program of skeletal muscles with regard to phenotype as assessed by MHC protein expression. The proportions of the various MHC isoforms were essentially the same in the IL-6 infused, contralateral (IL-6C) and Sham muscles (Fig. 3 and data...
not shown). Similarly, IL-6 infusion did not effect the classical training induced alteration in MHC profile of the R-IL-6 rats (Fig. 3).

The pool of total RNA present in muscle consists primarily (>85%) of ribosomal RNA (rRNA). As such, substantial increases in this parameter are thought to reflect an increase in potential translational capacity (i.e., more ribosomes) (40). IL-6 infusion per se had no effect on the amount of RNA in muscle (Fig. 11). Neither did running change this value. However, the combination of IL-6 infusion and running resulted in an increase in RNA (Fig. 11). The fact that the level of RNA in the growth impaired IL-6C infused muscles was unchanged, while it increased in the IL-6 infused muscles of the runners, suggests that one of the impacts of IL-6 infusion may be a decrease in translational efficiency (i.e., protein per unit RNA). This conclusion is supported by the significant decrease in the protein to RNA ratio seen in both the IL-6C and IL-6R muscles (Fig 11B). This interpretation would suggest that running stimulated a compensatory increase in rRNA enabling these muscles to overcome the IL-6 induced defect and maintain protein production and therefore growth. However, this compensatory response did not appear to alter the decline in translational efficiency in that the protein to RNA ratios were the same in both the sedentary and running groups (Fig. 11A).

**IL-6 INDEPENDENT EXERCISE EFFECTS.** A number of changes in muscle appeared to be independent of the IL-6 treatment. Perhaps most interesting was the training induced increase in the level of mRNA for the IL-6 receptor (IL-6R). The magnitude of this increase was similar in both the infused and contralateral muscles of the runners (Fig. 4). It could be speculated that this response reflects some relationship with the well established role of acute, exercise induced, increases in IL-6 expression (26). In support of this, Keller et al. reported that endurance training increased IL-6R mRNA expression in human muscle (45).

Exercise training appeared to decrease the level of mRNA for SOCS2 and CIS, two members of the suppressor of cytokine signaling (SOCS) family that are very similar in structure (75). SOCS2 and CIS are thought to play a role in negative feed back to GH signaling thereby limiting the anabolic, growth related, effects of that growth factor (34, 66). However, there are reports that, in some tissues, SOCS2 can inhibit IGF-I regulated growth as well (e.g., 56).
We have previously reported that resistance exercise can depress SOCS2 mRNA in rat skeletal muscle (38). In that context, we assumed that this was associated with responses that would promote muscle hypertrophy. However, endurance mode exercise training, such as voluntary running in the current study, is not generally associated with muscle hypertrophy (63). It is possible that the changes in SOCS2 and CIS observed in the current study may reflect negative feedback associated with running exercise-induced increases in GH possibly functioning as a regulatory element in the control of glucose homeostasis as opposed to a growth related role (14, 44, 85).

**EXERCISE INDEPENDENT IL-6 EFFECTS.** IL-6 infusion stimulated an increase in the production and/or accumulation of the mRNA for TNFα and its receptor in the gastrocnemius muscles of rats (Fig. 12A). The finding that the mRNA for TNFα and its receptor was increased by IL-6 was unexpected. Studies imposing systemic increases in IL-6 generally report that TNFα levels are suppressed. For example Starkie et al. reported that exogenous IL-6 repressed endotoxin-induced increases in plasma TNF-α in humans (74). While other studies have indicated that IL-6 can increase circulating TNF-α (43), this has not been a common finding (62). When attempting to interpret the current findings, it is important to note that the treatment was localized to muscle and that the changes in TNF related mRNA were observed in the targeted muscle. If, in fact, the increased TNF-α was realized as protein, it had no systemic manifestation (Fig. 2) and thus may not be at odds with previous reports.

The levels of mRNA for SOCS3 were significantly increased in both groups of IL-6 infused muscles (Fig. 12C). As noted above, one known role for SOCS3 is negative feedback to IL-6 receptor signaling via the inhibition of Janus Kinases (JAK) activity (6, 75). The induction of SOCS3 mRNA is thought to underlie the growth impairment observed in transgenic mice over expressing IL-6 (53). One possible mechanism for IL-6 induced growth impairment may be the known reliance of GH, IGF-I and insulin on JAK signaling cascades. This commonality in signaling intermediates renders these growth factors sensitive to inhibition by increased levels of SOCS3 (33, 67, 71, 78, 82). In addition to the canonical Jak/STAT pathway associated with SOCS, there is a growing body of evidence which indicates that SOCS proteins and in particular SOCS3, interact
with and inhibit receptor mediated activation of insulin receptor substrate (IRS) (50). IRS is a key initial mediator of insulin and IGF-I signaling both of which can promote anabolism in skeletal muscle. Taken together, the results from the literature suggest that one mechanism by which IL-6 might promote catabolic effects in skeletal muscle may be via SOCS3 mediated inhibition of signaling pathways associated with anabolic stimuli. In the context of an immune response, the rationale for this mechanism is clear. One of the primary responses to physiological insults such as infection is a mobilization of resources such as amino acids from skeletal muscle. IL-6 stimulated SOCS feed back may serve to coordinately suppress competing anabolic processes to prevent a futile cycle of protein synthesis at a time when amino acid mobilization is required.

In the current study, exercise did not alter the IL-6 induced increase in SOCS3 mRNA (Fig 12C). This would suggest that the “protective” effects of exercise on growth do not directly involve down regulation of IL-6 related signaling.

**EXERCISE - IL-6 INTERACTIONS** Most notably, voluntary running exercise normalized muscle growth (Fig.6). A number of additional IL-6 induced changes in skeletal muscle appeared to be, to some extent, countered by exercise.

As we observed previously in adult rats (39), local IL-6 exposure stimulated an increase in the mRNA for IGF-I in the muscles of growing rats. However, this effect was eliminated by the running protocol. We speculate that the increase in IGF-I mRNA may represent a compensatory response, possibly to decreased efficacy of IGF-I intracellular signaling, essentially resulting in resistance to IGF-I. In support of this hypothesis, there was a significant increase in IGF-I/Insulin receptor protein in the IL-6 infused vs. contralateral muscles (Fig. 8). It is possible that exercise in some way normalized IGF-I signaling obviating the stimulus for this compensatory response. In support of this, running induced similar increases in IGFR1 in both the contralateral and IL-6 infused muscles suggesting that the effects of running obviated the stimulus for a compensatory response to IL-6 induced interference with IGF-I signaling (Fig. 8).

Increased Procollagen III mRNA (Fig. 9) is often seen in parallel with increased levels of IGF-I (2, 60). However, in each case this was a function of increased mechanical loading. In the current study, the changes observed in Procollagen III mRNA levels appear to directly mirror the IGF-I response to these treatments and were
significantly correlated (r= 0.40, p=0.007). Taken together with the increased IGF-I mRNA seen in this and our previous IL-6 infusion study, this result suggests that the compensatory IGF-I response may be ineffective in conserving muscle contractile protein but effective in stimulating increased collagen mRNA.

Atrogin is a muscle specific ubiquitin E3 ligase that has been associated with muscle protein turnover (30). In the current study, atrogin mRNA was increased in the growth retarded IL-6 infused muscles (Fig. 10A), possibly indicating an increase in the protein degradation machinery of these muscles. Exercise appeared to partially blunt this effect of IL-6 such that an increase in atrogin mRNA could not be detected statistically.

Similar to atrogin, the expression of cyclin dependent kinase inhibitor p21 was increased by IL-6 infusion and this effect was partially blunted by running (Fig. 10B). Increased p21 expression is generally associated with the inhibition of cell proliferation. It is possible that, in the current context, increased p21 mRNA may be related to a down regulation of the ongoing satellite cell proliferation associated with growth (70). In this context it is important to note that, the concentrations of DNA were similar in all of the muscles from this study. While this is a rather gross measure, it may indicate that the myonuclear compliment of the constituent muscle fibers of each muscle was appropriate for the myofiber size. This would allow for the speculation that one of the growth defects in the IL-6 muscles was a reduction in cell proliferation thereby limiting myofiber growth due to myonuclear domain limitations.

**Potential Study Limitations**

A potential limitation to the current study is the partial failure of the assumption that the localized infusion of IL-6 would have no systemic effects. Analysis of the circulating levels of IL-6 and IL-1β indicated that there were decreases in the circulating levels of these proteins in the IL-6 infused rats. This is somewhat surprising in that the dose of IL-6 delivered to the muscle was extremely low. For example, if the entire output of IL-6 was delivered directly into the circulation, as opposed to the muscle interstitial space, it would represent concentration of 0.04pg / ml. By comparison, the recent work by van Hall et al. achieved sustained plasma IL-6 concentrations 140 pg / ml. Since the Sham group animals were handled in every respect the same as the two IL-6 treatment groups, it is clear that these results are
related to the IL-6 treatment. We do not however, feel that this substantially compromised the findings of this study. IL-6 infusion had no apparent effects on the somatic growth of the rats, the growth of the heart or of the contralateral and adjacent ipsilateral skeletal muscles.

SUMMARY: Studies have found that acute elevation of IL-6 results in a negative protein balance in skeletal muscle (86), while chronic IL-6 exposure results in a growth deficit that can be countered by IL-6 neutralization (7, 20, 21, 84, 69) sometimes in the absence of changes in the state of inflammation (69).

The primary finding of the current study, that IL-6 delivered directly to a skeletal muscle inhibited the growth of that muscle, contributes to this growing body of evidence which indicates that chronic elevations in IL-6 per se may be mediating the catabolic effects of some disease states.

The implications of this research are that IL-6 elevation may be a promising and important candidate for therapy aimed at protecting growth in children with chronic inflammation. Further, these results indicate that, with regard to the growth of skeletal muscle, appropriate volumes of exercise do no harm and may provide a protective effect.
| Target mRNA | PCR Primer sequence 5'→3' | Product Size (bp) | GenBank Acc. # |
|-------------|---------------------------|-------------------|---------------|
| IL6         | Fwd: CAGAAATACAAAGAAATGATGGATGCT  
              Rev: ATTGGAAGTTGGGTAGGAAAGGAC | 242              | NM_012589     |
| IL6 receptor| Fwd: AGGTGGCCCAGCATCAATGTGCTCA  
              Rev: TTCCGTACTGATCCCTCGTGTGTCATAGT | 228              | NM_017020.2   |
| TNFα        | Fwd: GGGGGCCTCCAGAATCC  
              Rev: TGGGCTACGGGGCTGTCAC | 218              | NM_012675.2   |
| TNFα receptor| Fwd: ACTGTGCCGGCAGGATGTGTTACCC  
               Rev: GAAGCCAGGCGCCACTGCTCA | 215              | NM_130426     |
Acknowledgments: The authors wish to thank Phuc Tran, Alvin Yu, Jasleen Saini, Marinelle Camilon, Tiffany Yu, Julianne Lynn, Phillip Bucur, Sandy Liu and Nkiruka Ojukwu for their technical support. This work was supported by NIH P01HD048721 (Project 1, G. Adams).
Figure Legends

Figure 1. Changes in body mass during 14 days of localized muscle infusion of vehicle (Sham), IL-6 or IL-6 plus concurrent voluntary running. #, P<0.05 vs. Sham and IL-6.

Figure 2. Blood plasma concentrations of selected cytokines during 14 days of localized muscle infusion of vehicle (Sham), IL-6 or IL-6 plus concurrent voluntary running. *, P<0.05 vs. Sham.

Figure 3. The effects of 14 days of localized muscle infusion of vehicle (Sham), IL-6 or IL-6 plus concurrent voluntary running on myosin heavy chain type IIa (A) and type IIb (B) protein proportions in rat medial gastrocnemius (MG) muscles. CON = contralateral muscle(open bar), INF = IL-6 infused muscle (grey bar). 1, P<0.05 vs. Sham; 2, P<0.05 vs. sedentary IL-6 contralateral; 3, P<0.05 vs. sedentary IL-6 infused.

Figure 4. The effects of 14 days of localized muscle infusion of vehicle (Sham), IL-6 or IL-6 plus concurrent voluntary running on IL-6 receptor mRNA levels in rat MG muscles. 1, P<0.05 vs. Sham; 2, P<0.05 vs. sedentary IL-6 contralateral; 3, P<0.05 vs. sedentary IL-6 infused.

Figure 5. The effects of 14 days of localized muscle infusion of vehicle (Sham), IL-6 or IL-6 plus concurrent voluntary running on mRNA levels for CIS (A) and SOCS2 (B) in rat MG muscles. 2, P<0.05 vs. sedentary IL-6 contralateral; 3, P<0.05 vs. sedentary IL-6 infused.

Figure 6. The effects of 14 days of localized muscle infusion of vehicle (Sham), IL-6 or IL-6 plus concurrent voluntary running on MG muscle total (A) and myofibrillar (B) protein content. 1, P<0.05 vs. Sham; 2, P<0.05 vs. sedentary IL-6 contralateral; 4, P<0.05 vs. run contralateral muscle; 5, P<0.05 vs. IL-6 infused run muscle.

Figure 7. The effects of 14 days of localized muscle infusion of vehicle (Sham), IL-6 or IL-6 plus concurrent voluntary running on the level of IGF-I (A) and IGFBP4 (B) mRNA present in rat MG muscle. 1, P<0.05 vs. Sham; 2, P<0.05 vs. sedentary IL-6 contralateral; 4, P<0.05 vs. run contralateral muscle.

Figure 8. The effects of 14 days of localized muscle infusion of vehicle (Sham), IL-6 or IL-6 plus concurrent voluntary running on the IGF-I/Insulin Receptor protein level present in rat MG muscle. 1, P<0.05 vs. Sham; 2, P<0.05 vs. sedentary IL-6 contralateral.

Figure 9. The effects of 14 days of localized muscle infusion of vehicle (Sham), IL-6 or IL-6 plus concurrent voluntary running on the level of procollagen III mRNA present in rat MG muscle. 1, P<0.05 vs. Sham; 2, P<0.05 vs. sedentary IL-6 contralateral; 4, P<0.05 vs. run contralateral muscle.
Figure 10. The effects of 14 days of localized muscle infusion of vehicle (Sham), IL-6 or IL-6 plus concurrent voluntary running on the level of Atrogin (A) and p21 (B) mRNA present in rat MG muscle. 1, P<0.05 vs. Sham; 2, P<0.05 vs. sedentary IL-6 contralateral; 4, P<0.05 vs. run contralateral muscle.

Figure 11. The effects of 14 days of localized muscle infusion of vehicle (Sham), IL-6 or IL-6 plus concurrent voluntary running on the amount of total RNA (A) and the ratio of Total Protein to Total RNA (B) present in rat MG muscle. 1, P<0.05 vs. Sham; 2, P<0.05 vs. sedentary IL-6 contralateral; 4, P<0.05 vs. run contralateral muscle.

Figure 12. The effects of 14 days of localized muscle infusion of vehicle (Sham), IL-6 or IL-6 plus concurrent voluntary running on the level of TNFα (A), TNFα receptor (B) present in rat MG muscle. 1, P<0.05 vs. Sham; 2, P<0.05 vs. sedentary IL-6 contralateral; 4, P<0.05 vs. run contralateral muscle.

Figure 13. The effects of 14 days of localized muscle infusion of vehicle (Sham), IL-6 or IL-6 plus concurrent voluntary running on the level of SOCS3 mRNA and protein present in rat MG muscle. Representative immunoblot for SOCS3 protein (A), SOCS3 protein in densitometer units (N.S.) (B), SOCS3 mRNA. 1, P<0.05 vs. Sham; 2, P<0.05 vs. sedentary IL-6 contralateral; 4, P<0.05 vs. run contralateral muscle.
References

1. Adams, G.R., F. Haddad and K.M. Baldwin. Time course of changes in markers of myogenesis in overloaded rat skeletal muscles. *J. Appl. Physiol.* 87:1705-1712, 1999.

2. Adams, G.R., F. Haddad, P.W. Bodell, P.D. Tran and K.M. Baldwin. Combined isometric, concentric and eccentric resistance exercise prevents unloading induced muscle atrophy in rats. *J. Appl. Physiol* 103(5):1644-1654, 2007.

3. Adams, G.R., B.M. Hather, K.M. Baldwin and G.A. Dudley. Skeletal muscle myosin heavy chain composition and resistance training. *J. Appl. Physiol.* 74:911-915, 1993.

4. Adams, G.R. and S.A. McCue. Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. *J. Appl. Physiol.* 84:1716-1722, 1998.

5. Al-Khalili, L., K. Bouzakri, S. Glund, F. Lonnqvist, H.A. Koistinen and A. Krook. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. *Mol Endocrinol* 20:3364-3375, 2006.

6. Aringer, M., A. Cheng, J.W. Nelson, M. Chen, C. Sudarshan, Y.J. Zhou and J.J. O'Shea. Janus kinases and their role in growth and disease. *Life Sci.* 64:2173-2186, 1999.

7. Ballinger, A. Fundamental mechanisms of growth failure in inflammatory bowel disease. *Horm Res.* 58 Suppl 1:7-10, 2002.

8. Banu, M.J., P.B. Orhii, W. Mejia, R.J. McCarter, L. Mosekilde, J.S. Thomsen and D.N. Kalu. Analysis of the effects of growth hormone, voluntary exercise, and food restriction on diaphyseal bone in female F344 rats. *Bone.* 25(4):469-480, 1999.

9. Bartoccioni, E., D. Michaelis and R. Hohlfeld. Constitutive and cytokine-induced production of interleukin-6 by human myoblasts. *Immunol. Let.* 42:135-138, 1994.

10. Bickel, C.S., J. Slade, E. Mahoney, F. Haddad, G.A. Dudley and G.R. Adams. Time course of molecular responses of human skeletal muscle to acute bouts of resistance exercise. *J Appl Physiol.* 98:482-488, 2005.

11. Bickel, C.S., J.M. Slade, F. Haddad, G.R. Adams and G.A. Dudley. Acute molecular responses of skeletal muscle to resistance exercise in able-bodied and spinal cord-injured subjects. *J Appl Physiol* 94:2255-2262, 2003.
12. Bolster, D.R., S.J. Crozier, S.R. Kimball and L.S. Jefferson. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. *J Biol Chem.* 277:23977-23980, 2002.

13. Cantini, M., M.L. Massimino, E. Rapizzi, K. Rossini, C. Catani, L.D. Libera and U. Carraro. Human satellite cell proliferation in vitro is regulated by autocrine secretion of IL-6 stimulated by a soluble factor(s) released by activated monocytes. *Biochem. Biophys. Res. Com.* 216:49-53, 1995.

14. Cappon, J.P., E. Ipp, J.A. Brasel and D.M. Cooper. Acute effects of high fat and high glucose meals on the growth hormone response to exercise. *J Clin Endocrinol Metab.* 76(6):1418-1422, 1993.

16. Carrizo, G.J., R. Wu, X. Cui, A.J. Dwivedi, H.H. Simms and P. Wang. Adrenomedullin and adrenomedullin-binding protein-1 downregulate inflammatory cytokines and attenuate tissue injury after gut ischemia-reperfusion. *Surgery* 141(2):245-253, 2007.

17. Chakravarthy, M.V., B.S. Davis and F.W. Booth. IGF-I restores satellite cell proliferative potential in immobilized old skeletal muscle. *J. Appl. Physiol.* 89:1365-1379, 2000.

18. Chomczynski, P. and N. Sacchi. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* 162:156-159, 1987.

19. Cohen, T., D. Nahari, L.W. Cerem, G. Neufeld and B.Z. Levi. Interleukin 6 induces the expression of vascular endothelial growth factor. *J. Bio. Chem.* 271:736-741, 1996.

20. DeBenedetti, F., T. Alonzi, A. Moretta, D. Lazzaro, P. Costa, V. Poli, A. Martini, G. Ciliberto and E. Fattori. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-1. A model for stunted growth in children with chronic inflammation. *J. Clin. Invest.* 99:643-650, 1997.

21. DeBenedetti, F., C. Meazza, M. Oliveri, P. Pignatti, M. Vivarelli, T. Alonzi, E. Fattori, S. Garrone, A. Barreca and A. Martini. Effect of IL-6 on IGF binding protein-3: a study
in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. *Endocrinology* 142:4818-4826, 2001.

22. Diehl, K.H., R. Hull, D. Morton, R. Pfister, Y. Rabemampianina, D. Smith, J.M. Vidal and C. vandeVorstenbosch. A good practice guide to the administration of substances and removal of blood, including routes and volumes. *J Appl Toxicol* 21:15-23, 2001.

23. Dogan, Y., S. Akarsu, B. Ustundag, E. Yilmaz and M.K. Guroze. Serum IL-1beta, IL-2, and IL-6 in insulin-dependent diabetic children. *Mediators Inflamm.* 59206:1-6, 2006.

24. Dubbelhuis, P.F. and A.j. Meijer. Hepatic amino acid-dependent signaling is under the control of AMP-dependent protein kinase. *FEBS Lett.* 521:39-42, 2002.

25. Eckel, L.A., T.A. Houpt and N. Geary. Spontaneous meal patterns in female rats with and without access to running wheels. *Physiol Behav.* 70(3-4):397-405, 2000.

26. Febbraio, M.A., N. Hiscock, M. Sacchetti, C.P. Fischer and B.K. Pedersen. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. *Diabetes.* 53:1643-1648, 2004.

27. Garma, T., C. Kobayashi, F. Haddad, G.R. Adams, P.W. Bodell and K.M. Baldwin. Similar acute molecular responses to equivalent volumes of isometric, lengthening, or shortening mode resistance exercise. *J Appl Physiol* 102(1):135-143, 2007.

28. Glund, S., A. Deshmukh, Y.C. Long, T. Moller, H.A. Koistinen, K. Caidahl, J.R. Zierath and A. Krook. Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. *Diabetes.* 56(6):1630-1637, 2007.

29. Goldstein, S.L., J.C. Leung and D.M. Silverstein. Pro- and anti-inflammatory cytokines in chronic pediatric dialysis patients: effect of aspirin. *Clin J Am Soc Nephrol.* 1(5):979-986, 2006.

30. Gomes, M.D., S.H. Lecker, R.T. Jagoe, A. Navon and A.L. Goldberg. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. *Proc Natl Acad Sci USA* 98(25):14440-14445, 2001.

31. Goodman, M.N. Interleukin-6 induces skeletal muscle protein breakdown in rats. *Proc Soc Exp Biol Med.* 205:182-185, 1994.
32. Gornall, A.G., C.J. Bardawill and M.M. David. Determination of serum proteins by means of the biuret reaction. *J. Biol. Chem. 177*:751-766, 1949.

33. Greenhalgh, C.J. and W.S. Alexander. Suppressors of cytokine signalling and regulation of growth hormone action. *Growth Horm IGF Res. 14(3)* :200-206, 2004.

34. Greenhalgh, C.J., E. Rico-Bautista, M. Lorentzon, A.L. Thaus, P.O. Morgan, T.A. Willson, P. Zervoudakis, D. Metcalf, I. Street, N.A. Nicola, A.D. Nash, L.J. Fabri, G. Norstedt, C. Ohlsson, A. Flores-Morales, W.S. Alexander and D.J. Hilton. SOCS2 negatively regulates growth hormone action in vitro and in vivo. *J Clin Invest. 115(2)* :397-406, 2005.

35. Hacham, M., N. Cristal, R.M. White, S. Segal and R.N. Apte. Complementary organ expression of IL-1 vs. IL-6 and CSF-1 activities in normal and LPS-injected mice. *Cytokine 8* :21-31, 1996.

36. Haddad, F. and G.R. Adams. Inhibition of MAP/ERK kinase prevents IGF-I induced hypertrophy in rat muscles. *J Appl Physiol.96* :203-210, 2004.

37. Haddad, F. and G.R. Adams. Acute cellular and molecular responses to resistance exercise. *J Appl Physiol 93(1)* :394-403, 2002.

38. Haddad, F. and G.R. Adams. Aging Sensitive Cellular and Molecular Mechanisms Associated with Skeletal Muscle Hypertrophy. *J Appl Physiol 100(4)* :1188-1203, 2006.

39. Haddad, F., F.P. Zaldivar, D.M. Cooper and G.R. Adams. IL-6 Induced Skeletal Muscle Atrophy. *J Appl Physiol 98(3)* :911-917, 2005.

40. Hannan, K.M., R.D. Hannan and L.I. Rothblum. Transcription by RNA polymerase I. *Front Biosci. 3* :376-398, 1998.

41. Hibbert, J.M., L.L. Hsu, S.J. Bhathena, I. Irune, B. Sarfo, M.S. Creary, B.E. Gee, A.I. Mohamed, I.D. Buchanan, A. Al-Mahmoud and J.K. Stiles. Proinflammatory cytokines and the hypermetabolism of children with sickle cell disease. *Exp Biol Med (Maywood) 230(1)* :68-74, 2005.

42. Holz, M.K., B.A. Ballif, S.P. Gygi and J. Blenis. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. *Cell. 123(4)* :569-580, 2005.
43. Huber, S.A., P. Sakkinen, D. Conze, N. Hardin and R. Tracy. Interleukin-6 exacerbates early atherosclerosis in mice. *Arterioscler Thromb Vasc Biol.* 19(10):2364-2367, 1999.

44. Jørgensen, J.O., L. Møller, M. Krag, N. Billestrup and J.S. Christiansen. Effects of growth hormone on glucose and fat metabolism in human subjects. *Endocrinol Metab Clin North Am.* 36(1):75-87, 2007.

45. Keller, C., A. Steensberg, A.K. Hansen, C.P. Fischer, P. Plomgaard and B.K. Pedersen. Effect of exercise, training, and glycogen availability on IL-6 receptor expression in human skeletal muscle. *J Appl Physiol.* 99(6):2075-2078, 2005.

46. Kimball, S.R. Interaction between the AMP-activated protein kinase and mTOR signaling pathways. *Med Sci Sports Exerc.* 38(11):1958-1964, 2006.

47. Koçtürk, S., B.M. Kayatekin, H. Resmi, O. Açikgöz, C. Kaynak and E. Ozer. The apoptotic response to strenuous exercise of the gastrocnemius and solutes muscle fibers in rats. *Eur J Appl Physiol.* 102(5):515-524, 2008.

48. Krause, U., L. Bertrand and L. Hue. Control of p70 ribosomal protein S6 kinase and acetyl-CoA carboxylase by AMP-activated protein kinase and protein phosphatases in isolated hepatocytes. *Eur. J. Biochem.* 269:3751-3759, 2002.

49. Labarca, C. and K. Paigen. A simple, rapid, and sensitive DNA assay procedure. *Anal. Biochem.* 102:344-352, 1980.

50. Lebrun, P. and E. VanObberghen. SOCS proteins causing trouble in insulin action. *Acta Physiol (Oxf).* 192(1):29-36, 2008.

51. Levälampi, T., V. Honkanen, P. Lahdenne, R. Nieminen, M. Hakala and E. Moilanen. Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis. *Scand J Rheumatol.* 36(3):189-193, 2007.

52. Lieskovska, J., D. Guo and E. Derman. IL-6-overexpression brings about growth impairment potentially through a GH receptor defect. *Growth Horm IGF Res* 12:388-398, 2002.
53. Lieskovska, J., D. Guo and E. Derman. Growth impairment in IL-6-overexpressing transgenic mice is associated with induction of SOCS3 mRNA. *Growth Horm IGF Res.* 13:26-35, 2003.

54. Ling, P.R., J.H. Schwartz and B.R. Bistrian. Mechanisms of host wasting induced by administration of cytokines in rats. *Am. J. Physiol.* 272:E333-E339, 1997.

55. Lotito, A.P., A. Campa, C.A. Silva, M.H. Kiss and S.B. Mello. Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis. *J Rheumatol.* 34(4):823-830, 2007.

56. Michaylira, C.Z., J.G. Simmons, N.M. Ramocki, B.P. Scull, K.K. McNaughton, C.R. Fuller and P.K. Lund. Suppressor of cytokine signaling-2 limits intestinal growth and enterotrophic actions of IGF-I in vivo. *Am J Physiol* 291(3):G472-G481, 2006.

57. Natali, A.J., L.A. Wilson, M. Peckham, D.L. Turner, S.M. Harrison and E. White. Different regional effects of voluntary exercise on the mechanical and electrical properties of rat ventricular myocytes. *J Physiol.* 541(Pt 3):863-875, 2002.

58. Nemet, D., C.M. Rose-Gottron, P.J. Mills and D.M. Cooper. Effect of water polo practice on cytokines, growth mediators, and leukocytes in girls. *Med Sci Sports Exerc.* 35(2):356-363, 2003.

59. Nemet, D., P. Wang, T. Funahashi, Y. Matsuzawa, S. Tanaka, L. Engelman and D.M. Cooper. Adipocytokines, body composition, and fitness in children. *Pediatr Res.* 53:148-152, 2003.

60. Olesen, J.L., K.M. Heinemeier, F. Haddad, H. Langberg, A. Flyvbjerg, M. Kjaer and K.M. Baldwin. Expression of insulin-like growth factor I, insulin-like growth factor binding proteins, and collagen mRNA in mechanically loaded plantaris tendon. *J Appl Physiol.* 101(1):183-188, 2006.

61. Ou, L.S., L.C. See, C.J. Wu, C.C. Kao, Y.L. Lin and J.L. Huang. Association between serum inflammatory cytokines and disease activity in juvenile idiopathic arthritis. *Clin Rheumatol.* 21(1):52-56, 2002.

62. Pedersen, B.K. IL-6 signalling in exercise and disease. *Biochem Soc Trans.* 35(Pt 5):1295-1297, 2007.
63. Putman, C.T., X. Xu, E. Gillies, I.M. MacLean and G.J. Bell. Effects of strength, endurance and combined training on myosin heavy chain content and fibre-type distribution in humans. *Eur J Appl Physiol.* 92(4-5):376-384, 2004.

64. Quinn, L.S., K.L. Haugk and K.H. Grabstein. Interleukin-15: A novel anabolic cytokine for skeletal muscle. *Endocrinol.* 136:3669-3672, 1995.

65. Raj, D.S., H. Shah, V.O. Shah, A. Ferrando, A. Bankhurst, R. Wolfe and P.G. Zager. Markers of inflammation, proteolysis, and apoptosis in ESRD. *Am J Kidney Dis.* 42(6):1212-1220, 2003.

66. Ram, P.A. and D.J. Waxman. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. *J. Biol. Chem.* 274:35553-35551, 1999.

67. Ridderstråle, M., J. Amstrup, D.J. Hilton, N. Billestrup and H. Tornqvist. SOCS-3 is involved in the downregulation of the acute insulin-like effects of growth hormone in rat adipocytes by inhibition of Jak2/IRS-1 signaling. *Horm Metab Res.* 35(3):167-177, 2003.

68. Ruderman, N.B., C. Keller, A.M. Richard, A.K. Saha, Z. Luo, X. Xiang, M. Giralt, V.B. Ritov, E.V. Menshikova, D.E. Kelley, J. Hidalgo, B.K. Pedersen and M. Kelly. Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome. *Diabetes.* 55 Suppl 2:S48-S54, 2006.

69. Sawczenko, A., O. Azooz, J. Paraszczuk, M. Idestrom, N.M. Croft, M.O. Savage, A.B. Ballinger and I.R. Sanderson. Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. *Proc Natl Acad Sci U S A.* 102(37):13260-13265, 2005.

70. Schultz, E. and K.M. McCormick. Skeletal muscle satellite cells. *Rev. Physiol. Biochem. Pharamcol.* 123:213-257, 1994.

71. Shi, H., I. Tzameli, C. Bjorbaek and J.S. Flier. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. *J Biol Chem.* 279:34733-34740, 2004.
72. Sjöholm, A. and T. Nyström. Inflammation and the etiology of type 2 diabetes. *Diabetes Metab Res Rev.* 22(1):4-10, 2006.

73. Solaro, J., D.C. Pang and F.N. Briggs. The purification of cardiac myofibrils with Triton X-100. *Biochim. Biophys. Acta* 245:259-262, 1971.

74. Starkie, R.L., S.R. Ostrowski, S. Jauffred, M.A. Febbraio and B.K. Pedersen. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-a production in humans. *FASEB Journal* 17(8):884-886, 2003.

75. Starr, R. and D.J. Hilton. Negative regulation of the JAK/STAT pathway. *Bioessays* 21:47-52, 1999.

76. Steensberg, A., M.A. Febbraio, T. Osada, P. Schjerling, G. van Hall, B. Saltin and B.K. Pedersen. Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content. *J Physiol* 537:633-639, 2001.

77. Trayhurn, P. and I.S. Wood. Adipokines: inflammation and the pleiotropic role of white adipose tissue. *Br J Nutr.* 92(3):347-355, 2004.

78. Velloso, L.A., C.R. Carvalho, F.A. Rojas, F. Folli and M.J. Saad. Insulin signalling in heart involves insulin receptor substrates-1 and -2, activation of phosphatidylinositol 3-kinase and the JAK 2-growth related pathway. *Cardiovasc Res.* 40:96-102, 1998.

79. Wada, Y., M. Sato, M. Niimi, M. Tamaki, T. Ishida and J. Takahara. Inhibitory effects of interleukin-1 on growth hormone secretion in conscious male rats. *Endocrinology* 136:3936-3941, 1995.

80. Wolf, M., S. Bohm, M. Brand and G. Kreymann. Proinflammatory cytokines interleukin 1 beta and tumor necrosis factor alpha inhibit growth hormone stimulation of insulin-like growth factor I synthesis and growth hormone receptor mRNA levels in cultured rat liver cells. *Eu. J. Endocrinol.* 135:729-737, 1996.

81. Wright, C., F. Haddad, A. Qin and K.M. Baldwin. Analysis of myosin heavy chain mRNA expression by RT-PCR. *J. Appl. Physiol.* 83(4):1389-1396, 1997.

82. Yadav, A., A. Kalita, S. Dhillon and K. Banerjee. JAK/STAT3 pathway is involved in survival of neurons in response to insulin-like growth factor and negatively regulated by suppressor of cytokine signaling-3. *J Biol Chem.* 280(36):31830-31840, 2005.
83. Yilmaz, E., B. Ustundag, Y. Sen, S. Akarsu, A.N. Kurt and Y. Dogan. The levels of Ghrelin, TNF-alpha, and IL-6 in children with cyanotic and acyanotic congenital heart disease. *Mediators Inflamm.* 32:403:1-5, 2007.

84. Yokota, S., T. Miyamae, T. Imagawa, N. Iwata, S. Katakura, M. Mori, P. Woo, N. Nishimoto, K. Yoshizaki and T. Kishimoto. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. *Arthritis Rheum.* 52(3):818-825, 2005.

85. Zoladz, J.A., K. Duda, S.J. Konturek, Z. Sliwowski, T. Pawlik and J. Majerczak. Effect of different muscle shortening velocities during prolonged incremental cycling exercise on the plasma growth hormone, insulin, glucose, glucagon, cortisol, leptin and lactate concentrations. *J Physiol Pharmacol.* 53(3):409-422, 2002.

86. vanHall, G., A. Steensberg, C. Fischer, C. Keller, K. Møller, P. Moseley and B.K. Pedersen. Interleukin-6 markedly decreases skeletal muscle protein turnover and increases non-muscle amino acid utilization in healthy individuals. *J Clin Endocrinol Metab.* doi:10.1210/jc.2007-2223, 2008.

87. vanderMeer, M.J., C.G. Sweep, C.E. Rijnkels, G.J. Pesman, F.J. Tilders, P.W. Kloppenborg and A.R. Hermus. Acute stimulation of the hypothalamic-pituitary-adrenal axis by IL-1B, TNFa and IL-6: A dose response study. *J. Endocrinol. Invest.* 19:175-182, 1996.
A. IL-6 (pg/ml)

B. IL-1β (pg/ml)

C. TNF-α (pg/ml)

Sham | IL-6 | IL-6 Run

* indicates statistically significant difference.
A. Total Protein (mg)

- SHAM: 80, 1,2,4,5
- CON: 80
- INF: 80
- IL-6 Sedentary: 80
- IL-6 Run: 80

B. Myofibrillar Protein (mg)

- SHAM: 40, 1,2,4,5
- CON: 40
- INF: 40
- IL-6 Sedentary: 40
- IL-6 Run: 40
A. IL-6 Sedentary  IL-6 Run

30Kd

SHAM  CON  INF  CON  INF

B. IL-6 Sedentary  IL-6 Run

SOCS3 Protein

SHAM  CON  INF  CON  INF

C. SOCS-3 mRNA / 18s

SHAM  CON  INF  CON  INF